expense
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
Dianthus Therapeutics; Q3 2025 financial results; claseprubart; DNTH212; autoimmune disease; MaGic trial; CIDP CAPTIVATE trial; R&D expenses; net loss; $525M cash runway